Continuous Intravenous Infusion Combination Chemotherapy for Head and Neck Squamous Cell Carcinoma

Mf, Gonzalez; Jg, Valdivieso; Gp, Sartiano

doi:10.1159/000225858

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiographic findings of hydrothorax and pulmonary edema were noted from 0-24 hours before death in the cats given 60 mg/m2 cisplatin (Figs. [2][3][4][5]. The cat that received 40 mg/m2 cisplatin had very slight increased interstitial markings on thoracic radiographs taken 72 hours after receiving the drug.…”

Section: Group #2mentioning

confidence: 99%

Cisplatin Toxicity in Cats

Knapp

Richardson

DeNicola

et al. 1987

Veterinary Internal Medicne

View full text Add to dashboard Cite

Cisplatin (cis-diamminedichloroplatinum; Platinol, Bristol, Syracuse, NY) was administered to 11 cats, divided into three groups of experimental and clinical patients. In group 1, cisplatin was administered at a dose of 60 mg/m2 to four cats. In an attempt to avoid renal toxicity, saline diuresis was induced by administering 0.9% saline solution intravenously at a rate of 20 ml/kg/hr for 4 hours before and 2 hours after cisplatin administration. All four cats became dyspneic and died 48-96 hours after cisplatin administration. Postmortem findings included severe hydrothorax, pulmonary edema, and mediastinal edema. In group 2, four experimental cats entered a trial comparing the effects of saline diuresis and cisplatin (60 mg/m2) with the effects of saline diuresis and placebo (0.9% saline solution). The cats in the saline control group remained completely normal, while the cats that received cisplatin developed clinical signs and gross postmortem pulmonary changes identical to those in the first group of cats. Histopathologic examination showed that the alveolar septa were thickened and congested, and contained macrophages, occasional neutrophils, thrombi, and small foci of necrosis and fibrin. Microangiopathic changes were seen in the alveolar capillaries. In the third group, three additional cats were treated with a lower dose of cisplatin. Two cats that received 40 mg/m2 of cisplatin developed pulmonary changes similar to, but less severe than, those seen in the cats that received the higher dose of cisplatin. One cat treated with 20 mg/m2 of cisplatin showed no pulmonary changes ante mortem or post mortem. This series of 11 clinical and experimental cases identifies an apparent species-specific, dose-related, primary pulmonary toxicity of cisplatin in cats. (Journal of Veterinary Internal Medicine. 1987; 129-35) CISPLATIN (cis-diamminedichloroplatinum) is a widely used chemotherapeutic agent in humans.'-3 The most common indications for its use include testicular, ovarian, and head and neck carcinomas.'-6 Cisplatin's application to veterinary medicine has recently been described, and the drug has been used in the treatment of a variety of solid tumors inThe most frequently seen toxicities in humans and dogs include gastrointestinal toxicity, nephrotoxicity, and bone marrow suppres~ion.'-~ Less common toxicities in man include hypomagnesemia, hypocalcemia, cardiac toxicities, hyper-

show abstract

Section: Group #2mentioning

confidence: 99%

Cisplatin Toxicity in Cats

Knapp

Richardson

DeNicola

et al. 1987

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

Adjuvant Applications of Infusional Chemotherapy

Lokich¹,

Sugarbaker²

1987

Cancer Chemotherapy by Infusion

View full text Add to dashboard Cite

Chemotherapeutic management of head and neck cancer

Al‐Sarraf

1987

Cancer Metast Rev

View full text Add to dashboard Cite

The use of chemotherapy in patients with head and neck cancer is increasing. In patients with recurrent head and neck cancer, a large number of chemotherapeutic drugs have shown antitumor activity. These drugs are discussed, and factors which influence response rate and survival are examined. New agents and treatment, including specific agents for combination chemotherapy, are presented. There has been a search for new treatments or procedures in patients with previously untreated and locally advanced cancer of the head and neck. The results, including studies of combined modality therapy and chemotherapy after surgery, are discussed. Chemotherapy in tumor of the salivary glands is briefly discussed, followed by an examination of intra-arterial therapy.

show abstract

Continuous Intravenous Infusion Combination Chemotherapy for Head and Neck Squamous Cell Carcinoma

Cited by 6 publications

References 8 publications

Cisplatin Toxicity in Cats

Cisplatin Toxicity in Cats

Adjuvant Applications of Infusional Chemotherapy

Chemotherapeutic management of head and neck cancer

Contact Info

Product

Resources

About